Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: The potential and limitations of the established cytotoxic chemotherapy for acute myeloid leukemia have been assessed by recent large-scale clinical trials. A further progress would require the contribution of alternative approaches. RECENT FINDINGS: Early results from more specific, less toxic, targeted agents are now available. Major options under investigation are demethylating drugs and inhibitors of tyrosine kinases, farnesylation and angiogenesis. CONCLUSION: Some of the novel agents, such as demethylating drugs, appear predestined for prolonged maintenance treatment due to their delayed antileukemic mechanism.
No takes yet. Share an insight, caveat, or question.
Krug et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: